Fraiser Kansteiner - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Fraiser Kansteiner's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Fraiser Kansteiner
Verified
Staff Writer, Fierce Biotech
New York
Beats
healthcare pharmaceutical industry medicineBiotechnology
Pornography
Content
Recently departed CBER director warns FDA staff cuts could upend drug review timelines as early as next year: BMO
By Fraiser Kansteiner Verified| FiercePharma Verified One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they could imperil the drug approval process that has served as the global regulatory standard for decades. On a recent call with analysts at BMO Capital Markets, an enigmatic “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—raised concerns that the roughly 3,500 layoffs at the agency under HHS secretary Robert F.
By Fraiser Kansteiner Verified| FiercePharma Verified As tariff threats and FDA staff cuts thrust the biopharma world into uncharted waters, President Donald Trump is offering the industry some reprieve by ordering the elimination of the so-called "pill penalty" baked into 2022’s Inflation Reduction Act.
Recently departed CBER director warns FDA staff cuts could upend drug review timelines as early as next year: BMO
By Fraiser Kansteiner Verified| FiercePharma Verified One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they could imperil the drug approval process that has served as the global regulatory standard for decades. On a recent call with analysts at BMO Capital Markets, an enigmatic “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—raised concerns that the roughly 3,500 layoffs at the agency under HHS secretary Robert F.
Company Info
Fierce Biotech
New York, United States